-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-505214-23-00
5
2024-06-07
colon carcinoma
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2023-504637-42-01
6
2023-12-21
aortic valve stenosis
-
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)
-
2024-514913-37-00
11
2023-01-12
Respiratory distress
-
2024-514025-30-00
4
2021-03-25
Ocular conservative treatment for retinoblastoma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
-
2024-518669-83-00
4
2024-12-05
acute promyelocytic leukemia (APL) in children and adolescents
-
2024-515870-28-00
5
2024-10-22
Moderate to severe systemic lupus erythematosus
-
2023-510178-15-00
5
2024-07-31
High-risk Large B-cell Lymphoma
-
2023-505972-32-00
5
2024-02-26
locally advanced anal squamous cell carcinoma
-
2022-501179-23-00
6
2023-03-08
atopic dermatitis
-
2024-514644-93-00
5
2022-12-09
Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
-
2023-507634-24-00
5
2022-05-20
Improper function of certain messenger materials in the body that cont
-
2024-516673-68-00
5
2020-10-27
Human papillomavirus (HPV)-positive oropharyngeal cancer